Department of General Surgery, Sher-i-Kashmir Institute of Medical Sciences, Medical College, Bemina, Sher-i-Kashmir Institute of Medical Sciences, Srinagar, Kashmir, India.
Saudi J Gastroenterol. 2011 Sep-Oct;17(5):343-7. doi: 10.4103/1319-3767.84493.
BACKGROUND/AIM: Hydatidosis has a worldwide distribution and the liver is the most common organ involved. Hydatid cysts of the liver can be managed either by nonoperative or operative methods. Nonoperative methods include chemotherapy and percutaneous treatment. The study aimed at understanding the effect of albendazole therapy on the viability of protoscoleces and recurrence rate of hydatid disease of the liver.
The study was conducted at Sher-i-Kashmir Institute of Medical Sciences, Soura, Srinagar, Kashmir, India, over a period of 2 years from January 2002 to December 2003, with further follow-up of 5 years. The study included 72 cases in the age group of 17-66 years, comprising 39 males and 33 females. The patients were randomized into two groups of 36 patients each. In group A, patients were directly subjected to surgery, while in group B, patients were administered albendazole for 12 weeks preoperatively, followed by a further postoperative course for 12 weeks.
Of patients who received albendazole therapy, no patient had viable cysts at the time of surgery, as compared to 94.45% of the patients who did not receive any preoperative albendazole (P<0.01). In patients who did not receive any albendazole therapy, recurrence rate was 16.66%, while no recurrence was seen in patients who received albendazole therapy (P≤0.05).
We conclude that albendazole is an effective adjuvant therapy in the treatment of hydatid liver disease.
背景/目的：包虫病分布于世界各地，肝脏是最常受累的器官。肝包虫囊肿可通过非手术或手术方法进行治疗。非手术方法包括化疗和经皮治疗。本研究旨在了解阿苯达唑治疗对原头蚴活力和肝包虫病复发率的影响。
该研究于 2002 年 1 月至 2003 年 12 月在印度克什米尔谢里·卡什米尔医学科学研究所进行，为期 2 年，并进行了 5 年的随访。该研究纳入了年龄在 17-66 岁之间的 72 例患者，包括 39 名男性和 33 名女性。患者随机分为两组，每组 36 例。在 A 组中，患者直接接受手术治疗，而在 B 组中，患者在术前接受阿苯达唑治疗 12 周，随后再接受 12 周的术后治疗。
接受阿苯达唑治疗的患者中，在手术时没有发现有活力的囊肿，而未接受任何术前阿苯达唑治疗的患者中，有 94.45%的患者有活力的囊肿（P<0.01）。未接受阿苯达唑治疗的患者复发率为 16.66%，而接受阿苯达唑治疗的患者无复发（P≤0.05）。
我们的结论是，阿苯达唑是治疗肝包虫病的有效辅助治疗方法。
